Long-term disease stabilization following treatment with erlotinib in heavily pretreated patients with wild-type epidermal growth factor receptor non-small-cell lung carcinoma: Two case reports

Lung adenocarcinomas carrying epidermal growth factor receptor (EGFR) mutations have been identified as a unique group of entities that depend on EGFR for their proliferation and metastasis. The introduction of reversible EGFR tyrosine kinase inhibitors, such as erlotinib, has significantly affected...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Mol Clin Oncol
Egile Nagusiak: Sakellakis, Minas, Koutras, Angelos, Pittaka, Maria, Tsitsopoulos, Efstathios, Kalofonou, Fotini, Kalofonos, Haralabos P.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: D.A. Spandidos 2016
Gaiak:
Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5228472/
https://ncbi.nlm.nih.gov/pubmed/28105360
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2016.1036
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak